Elite Pharmaceuticals Inc (ELTP)

[kayak_wench]

I think $2.5 is an upper bound.
I asked ChatCPT and it put the current valuation of Elite's core products minus Vyvanse at $0.27–$0.37
Elite's value with Vyvanse $0.58–$0.78
and then Value with core, Vyvanse, and blood thinner at $1.36–$1.82

The first two look reasonable to me because its what we are currently witnessing.

To figure out purchase price it said we may see a 60 to 100% acquisition premium (common for small, cash-generating, under-the-radar firms):
Meaning a strategic acquirer could justify $1.50–$3.00/share if it believes in Elite’s ability to capture Vyvanse share, launch the $27B-market ANDA, have future billion dollar products, and run at higher margins post-acquisition.

How it summarized it:

That’s because strategic buyers aren’t just buying Elite’s current profits — they’re buying future earnings, cost savings, and product potential that the public market often doesn’t fully value.

But until a sale we live without that acquisition premium. FYI, I think the premium will be closer to 60%, but that final value will depend on the number of BEs we have by the time of sale or nearly ready BEs (I'm sure another pharmaceutical company can judge whether work on a BE is nearly done).